The Patterson Perspective

A German tech firm's new platform offers a real-time map of grid capacity, aiming to solve a critical hurdle in North America's energy transition.

The fashion giant beat earnings and initiated a dividend, but declining sales and consumer uncertainty reveal a complex picture for the apparel industry.

A landmark $275M deal for a novel Hunter syndrome drug highlights a new frontier in treating brain diseases and a major shift in biotech funding.

A new FDA-approved drug, EMPAVELI, shows unprecedented results for two rare kidney diseases, offering hope to patients facing dialysis or transplant.

A new social media dictionary reveals the words that defined 2025, but its predictions for 2026 signal a growing battle between human authenticity and AI.

Akebia Therapeutics expands its pipeline, targeting rare kidney diseases with two novel drugs and offering new hope where treatment options are scarce.

Shipping giant Hafnia declares a robust Q3 dividend, backed by strong earnings and a bullish market outlook. Here’s what it means for investors.

With massive funding and a coordinated national strategy, a Chinese city is luring elite innovators. What can Canada learn from its aggressive talent hunt?

A nearly $1 million deal for AI-powered smart glasses is rolling out in Canada, signaling a major shift in warehouse work and supply chain efficiency.

Novartis's $560K Health Equity Initiative funds grassroots projects, highlighting a strategic shift in tackling Canada's deep-seated health disparities.

New solar-powered security systems with local storage are challenging the high cost and privacy risks of cloud subscriptions. Is this the future of home safety?

Shoppers Drug Mart's holiday event signals a shift where retailers blend community engagement with commerce, redefining the purpose of physical stores.

An animal health drug is on a fast track to treat ALS as a key partnership brings big pharma expertise to a promising biotech. What could this mean for patients?

A new bill aims to merge organ donation into Héma-Québec for efficiency, but critics fear it will gut the human expertise vital to saving lives.

With thousands waiting for sight-restoring surgery, a new network says dozens of clinics are ready to clear the backlog. Is Ontario ready to act?

As US tech faces turmoil, one Canadian firm bets on 'technological sovereignty' to secure the nation's most critical and front-line industries.

A major forecast predicts modest rate relief for Canadian households but warns of a complex year shaped by US policy, sticky inflation, and tech disruption.

With a new lung cancer drug approved and an obesity treatment in the wings, Amgen's investor talk is a key bellwether for biotech's future in Canada.

A routine investment announcement offers a window into the economic pressures shaping household stability and the future of Canadian public services.

PrairiesCan invests in MoveMobility & QDoc Inc., expanding access to healthcare for rural communities and driving economic growth through innovative medical vehicle manufacturing and virtual care solutions.